How ChondroFiller injection works in the hip joint

Hip articular cartilage — the smooth, load-bearing lining of the joint — is avascular and aneural, meaning it has almost no blood supply and no direct nerve connection to trigger the body's usual repair response. When a focal full-thickness defect develops, typically from femoroacetabular impingement (FAI), the tissue simply cannot regenerate on its own. That biological limitation is precisely why a restorative scaffold matters.

ChondroFiller injection addresses this by placing a CE-marked Class III acellular collagen type I hydrogel directly into the defect. In the current service pathway at Lincolnshire Hip, this is carried out as an ultrasound-guided outpatient procedure — no operating theatre, no general anaesthetic. Once in position, the scaffold works through matrix-induced chondrogenesis: rather than introducing any external cells, it creates a structurally organised environment that chemically attracts the patient's own progenitor cells into the defect site. A 2025 ex vivo study recorded a 2.4-fold increase in DNA content within the ChondroFiller scaffold by day 14, directly confirming this cell in-migration.

The treatment is indicated for focal full-thickness acetabular defects, typically above 2 cm², within the product's CE-marked range up to 3 cm² (extendable to 6 cm² in suitable cases). In published hip cohort data, the mean Harris Hip Score improvement following this approach is approximately 33 points — a result that exceeds the established threshold for a clinically meaningful gain.

What the hip-specific clinical evidence shows

The strongest direct hip-specific data comes from a prospective cohort published in the Journal of Hip Preservation Surgery in 2021 by Mazek and colleagues (n=26). All participants had femoroacetabular impingement alongside full-thickness acetabular defects exceeding 2 cm² and were followed for between 12 and 60 months after ChondroFiller gel was placed into the acetabular defect. At the 3–5 year mark, 17 of the 21 evaluable patients — 81% — maintained good or excellent outcomes, and only 2 of the original 26 required total hip replacement during the follow-up period. Pre-to-post MRI differences in the cohort were statistically significant, confirming measurable cartilage healing on imaging rather than symptom change alone. These results should be read alongside the study's limitations: a single-centre cohort of 26 patients, with no control arm, is an encouraging signal rather than definitive proof.

A separate 2021 paper by Perez-Carro corroborated the picture, confirming that injectable ChondroFiller is a viable approach for full-thickness acetabular defects while calling for larger, longer-term studies — a caveat that remains relevant in 2026.

To place these results within the broader landscape of injectable hip cartilage repair, a two-year prospective study of injectable matrix-associated autologous chondrocyte transplantation (NOVOCART Inject, n=21) offers a useful reference point. Patients with FAI-related full-thickness hip defects of comparable size saw iHOT33 scores rise from 52.9 to 85.8 over 24 months, with near-complete MRI defect fill confirmed in 11 of 14 evaluated hips. ChondroFiller injection outcomes sit within a similar range, suggesting the scaffold approach is consistent with what injectable hip cartilage repair techniques can achieve — rather than representing an outlier in either direction.

MOCART scores and what MRI reveals about healing

MOCART — Magnetic Resonance Observation of Cartilage Repair Tissue — is the standard MRI-based scoring tool used to quantify how well a repair scaffold has filled a cartilage defect, how completely the new tissue integrates with surrounding native cartilage, and how mature the repair surface appears on imaging. Scores run from 0 to 100; higher values reflect better defect fill, smoother surface contour, and more homogeneous tissue signal.

For ChondroFiller injection in the hip, published data place MOCART scores in the range of 70 to 87. That range indicates substantial defect fill and integration — sufficient to support functional recovery — though it does not necessarily imply complete restoration of native hyaline cartilage architecture. For most patients, functional outcome measures remain more directly meaningful than an imaging score in isolation; the MRI picture is best read alongside the clinical improvements discussed in the previous section.

MRI at 6–18 months post-injection shows significant defect healing in more than 90% of hip cases, suggesting early scaffold integration is both reliable and consistent. The healing process is progressive rather than immediate: a controlled, randomised multicentre trial examining ChondroFiller in knee cartilage defects — cited here as the best available evidence for scaffold maturation kinetics, rather than hip-specific outcomes — used MOCART assessments at four and 52 weeks and documented progressive cartilage maturation across the full year, with mean scores rising from approximately 65 at four weeks to 82 at 12 months.

It is worth noting that MOCART was not a primary endpoint in the Mazek 2021 hip cohort; the 70–87 range is therefore indicative rather than derived from a dedicated hip imaging primary outcome study. For comparison, arthroscopic minced cartilage implantation for acetabular defects produced a MOCART score of 87.2 ± 9.2 at two years — placing ChondroFiller's imaging range within the same order of magnitude as established hip cartilage repair benchmarks.

The recovery and healing timeline after ChondroFiller injection

The maturation arc from the knee evidence base offers the clearest illustration of what to expect after ChondroFiller injection. In a randomised multicentre trial, MOCART scores progressed from approximately 65 at four weeks to 82 at 12 months — a trajectory reflecting not a single repair event but a sustained biological process in which the collagen scaffold is gradually replaced by host-derived tissue. These figures come from knee studies, where the published ChondroFiller dataset is largest, and should be read as a directional guide rather than a precise hip-specific prediction; the underlying cellular mechanism is the same in both joints.

The process begins early. Within the first fortnight — consistent with ex vivo evidence confirming active cell in-migration into the scaffold — host progenitor cells start populating the collagen matrix. By six months, MRI typically shows substantial defect fill, and significant healing is evident on imaging in more than 90% of hip cases assessed at 6–18 months post-injection. Improvement continues through the first year and, for most patients, beyond.

The Mazek 2021 hip cohort — followed for 12 to 60 months — represents the most mature hip-specific dataset available. The 3–5 year results, with 17 of 21 evaluable patients achieving good or excellent outcomes, are the longest published follow-up for ChondroFiller in the hip, and most of the functional gain appears to consolidate within the first 12–24 months before stabilising in patients who met appropriate selection criteria.

Practically, patients should plan around a gradual arc of improvement rather than a sharp recovery peak. Because cartilage relies on slow cellular remodelling rather than a vascular healing response, the scaffold pathway is inherently a measured process — and expectations set around that timeline tend to reflect what the published evidence actually shows.

Who is a suitable candidate for ChondroFiller injection in the hip

Not every hip responds well to ChondroFiller injection — and understanding who is most likely to benefit is as important as understanding how the treatment works.

The published hip evidence points to a consistent selection profile. Ideal candidates are younger or active patients with an isolated, full-thickness acetabular cartilage defect larger than 2 cm², most commonly arising from femoroacetabular impingement (FAI). The key radiographic criterion is a Tönnis grade of 0 or 1, indicating that the joint space is well preserved and that widespread osteoarthritis is absent. The Mazek 2021 cohort — which produced the strongest hip-specific outcomes data — enrolled exclusively patients who met this profile, and it is within this group that 81% achieved good or excellent results at three to five years.

The contraindication is equally well defined and should not be softened. Patients with Tönnis grade 2 or 3 osteoarthritis consistently produced poor results in the published evidence. This reflects the biological reality that an injectable scaffold designed to repair a focal defect cannot restore a joint in which the surrounding cartilage surface is already substantially degraded. Widespread joint degeneration is outside the scope of what ChondroFiller injection can address.

In UK practice, patients are more commonly presented with Kellgren-Lawrence (KL) grading on their NHS imaging reports. KL grades I–III broadly correspond to the Tönnis 0–1 threshold; KL grade IV advanced OA is analogous to Tönnis 2–3 and carries the same implication — the joint is too far compromised for scaffold-based repair to produce reliable benefit.

Establishing which group a patient falls into, and whether defect characteristics are suitable, requires a formal hip assessment. Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral for that evaluation.

Gaps in the evidence and what they mean for patients

Three limitations define the current evidence base and are worth stating plainly.

First, no randomised controlled trial has been conducted specifically for ChondroFiller injection in the hip. The anchor study — Mazek 2021 — is a prospective cohort of 26 patients, not a controlled experiment with a comparator arm. The 2021 Perez-Carro ScienceDirect paper, which independently confirmed the procedure's viability for full-thickness acetabular defects, flagged that gap directly: larger and longer outcome studies are still required. That observation remains accurate in 2026.

Second, published follow-up data for hip-specific use extend to five years at most. What happens to the repair tissue beyond that horizon is inferred from the knee evidence base — where the dataset is considerably larger — and from the biological plausibility of a stable collagen-derived repair structure. That extrapolation is reasonable but is not the same as direct long-term hip evidence.

Third, the MOCART range of 70–87 cited in the hip context is a synthesis across multiple studies rather than a single reported endpoint from the Mazek cohort, which used MRI primarily to confirm healing rather than to report MOCART as a primary outcome measure.

None of these limitations invalidates the clinical case for ChondroFiller injection in appropriately selected patients — the existing evidence is consistent enough to support its use. What the gaps do require is realistic expectations: good outcomes are probable in the right hip, and the evidence base is still maturing.

1. [1] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: a cohort study with 12- to 60-month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002
2. [2] Minced Cartilage Implantation in Acetabular Cartilage Defects: 2-Year Results. (2023). https://doi.org/10.1177/19476035231189840 https://doi.org/10.1177/19476035231189840
3. [3] Controlled, randomized multicenter study: ChondroFiller liquid vs microfracturing, focal knee cartilage defects. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
4. [4] Ex Vivo Osteochondral Biomimetic Platform for Cartilage Regeneration Investigation (2025). (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
5. [5] Two-Year Results of Injectable MACT in the Hip Joint (NOVOCART Inject). (2023). https://doi.org/10.3390/jcm12175468 https://doi.org/10.3390/jcm12175468